Treatment Pathways and Healthcare Resource Use in Mantle Cell Lymphoma
Research type
Research Study
Full title
The THRUM Study - Treatment Pathways, Healthcare Resource Use and Clinical outcomes of Patients with Mantle Cell Lymphoma in England
IRAS ID
272752
Contact name
Adrian Paul Rabe
Contact email
Sponsor organisation
Health IQ
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Mantle cell lymphoma is a cancer involving specific types of white blood cells. Normal white blood cells function to protect the body as part of the immune system. In mantle cell lymphoma, these cells have mutated and now invade and harm different parts of the body. Being a very debilitating disease, it is important to understand how much resources they use up in the national health service, as well as the
various treatments they undergo, and how those treatments impact their survival. This study aims to use anonymized and pseudonymized data from Public Health England to construct a group of patients with advanced melanoma. Using the same dataset linked to secondary care and to the cancer treatment dataset, the study would determine healthcare resource use and treatment pathways, as well as clinical outcomes. The span of time covered would be from 2010 to the latest available
data when it would be requested. Once completed, this study would hopefully inform health policy to reduce healthcare resources and reconfigure services to provide better treatment pathways for patients.REC name
East Midlands - Nottingham 1 Research Ethics Committee
REC reference
19/EM/0307
Date of REC Opinion
21 Oct 2019
REC opinion
Favourable Opinion